Dr. Reddy's closes acquisition of Habitrol brand

摘要

Dr. Reddy's Laboratories has closed the acquisition of Habitrol brand, an over-the-counter nicotine replacement therapy transdermal patch, from Novartis Consumer Health Inc, following the issuance of the consent order from the US Federal Trade Commission (FTC) last month. The company had earlier entered into an asset purchase agreement with Novartis to acquire the title and rights of Habitrol brand and to mar- ket the product in the US. The company will begin the shipments of the product in the market shortly, it said. In October, the company has agreed to acquire this brand for an undisclosed sum. Habitrol has US sales of more than $58-mn, according to earlier reports.